FIRST trial: Lenalidomide with dexamethasone beats standard chemotherapy for multiple myeloma
1. Progression-free survival was improved by about 3 months with continuous lenalidomide-dexamethasone compared to standard melphalan-prednisone-thalidomide. 2. Overall survival was ...